# Workflow 5: Genomics-Driven Discovery of Microbial Natural Products

**Paper**: "Genomics-driven discovery of microbial natural products"

## Research Objective

- Leverage genome mining to overcome antibiotic resistance crisis
- Systematically discover novel natural product scaffolds
- Enable high-efficiency discovery pipeline from genomics to bioactivity

## Computational Workflow

### STEP 1: BGC Mining and Prioritization

**INPUT**: 
- Microbial genomic sequences (shotgun or long-read)
- Knowledge of drug-resistance genes
- Prioritization criteria (novelty, therapeutic potential)

**PROCESS**:
- Computational BGC identification and annotation
- Structural novelty assessment through genome mining tools
- Similarity comparison to known compounds
- Scaffold diversity analysis
- Phylogenetic context analysis

**OUTPUT**: 
- Prioritized list of novel/interesting BGCs
- Novelty scores and structural annotations
- **Feeds into**: Expression strategy selection

---

### STEP 2: Expression Strategy Selection

**INPUT**: 
- Priority BGCs from Step 1
- Available heterologous expression systems

**PROCESS**:
- Computational evaluation of heterologous vs. native expression
- Host compatibility predictions
- Metabolic pathway analysis
- Expression optimization strategy selection
- Pathway engineering requirements assessment

**OUTPUT**: 
- Selected expression approach with optimized parameters
- Host system specifications
- Pathway modifications if needed
- **Feeds into**: Pathway engineering

---

### STEP 3: Pathway Engineering for Production Optimization

**INPUT**: 
- Expression system from Step 2
- BGC structural information

**PROCESS**:
- Predictive modeling of rate-limiting steps
- Enzyme expression level optimization
- Precursor availability assessment and improvement
- Metabolic flux balance analysis
- Bottleneck identification and resolution strategies

**OUTPUT**: 
- Optimized pathway engineering specifications
- Expected production level improvements
- **Feeds into**: Regulatory manipulation or direct production

---

### STEP 4: Global Regulatory Manipulation Strategy

**INPUT**: 
- Optimized pathway from Step 3
- Target production level specifications

**PROCESS**:
- Computational design of regulatory modifications
- Prediction of pleiotropic effects
- Co-culture optimization modeling
- Environmental induction strategies
- Global gene expression modeling

**OUTPUT**: 
- Regulatory modification specifications
- Co-culture parameters
- Environmental conditions optimization
- **Feeds into**: Production and bioactivity screening

---

### STEP 5: Bioactivity Assessment and Drug Development

**INPUT**: 
- Produced compounds from optimized system
- Target bioactivity profiles

**PROCESS**:
- High-throughput bioactivity screening
- Mechanism of action prediction
- Structure-activity relationship analysis
- Lead optimization recommendations
- Clinical relevance assessment

**OUTPUT**: 
- Novel natural products with improved production levels
- New drug candidates addressing resistance
- Development recommendations

---

## Final Experimental Product

**Novel bioactive compounds** with:
- Genome-driven discovery approach
- Optimized production systems
- Characterized bioactivity
- Ready for preclinical/clinical development

## Key Computational Tools

- BGC mining: antiSMASH, MINER, ClusterMine
- Sequence analysis: BLAST, HMMsearch, FASTA
- Genome assembly: SPAdes, Velvet, DISCOVAR
- Metabolic modeling: COBRA, Gurobi, CPLEX
- Metabolic reconstruction: KBase, RAST
- Flux balance analysis: COBRApy, PSAMM
- Expression analysis: RBS Calculator, Promoter predictors
- Bioactivity prediction: Activity prediction ML models
- Co-culture modeling: Community simulation tools
